Ralph A. DeFronzo, MD, discusses the utilization of glucagon-like peptide-1 agonists and incorporating evidence-based guidelines into practice when considering the use of incretin-based therapies for type 2...
COPD affects more than 16 million Americans. During his session at the American Lung Association’s LUNGFORCE Expo, Andrew Berman, MD, discussed pharmacologic and nonpharmacologic therapy options for...